{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:04:16Z","timestamp":1794877456947,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1033751"],"award-info":[{"award-number":["OPP 1033751"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1033751"],"award-info":[{"award-number":["OPP 1033751"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13071-018-2655-5","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T10:30:07Z","timestamp":1517308207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-5058","authenticated-orcid":false,"given":"Jorge","family":"Cano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Gloria","family":"Bas\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"O\u2019Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afework H.","family":"Tekle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Wanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honorat G.","family":"Zour\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Pullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"issue":"9747","key":"2655_CR1","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","volume":"376","author":"MJ Taylor","year":"2010","unstructured":"Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010;376(9747):1175\u201385.","journal-title":"Lancet"},{"issue":"8","key":"2655_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1179\/136485906X112194","volume":"100","author":"M Boussinesq","year":"2006","unstructured":"Boussinesq M. Loiasis. Ann Trop Med Parasitol. 2006;100(8):715\u201331.","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"2655_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(16)30405-4","volume":"17","author":"CB Chesnais","year":"2017","unstructured":"Chesnais CB, Takougang I, Paguele M, Pion SD, Boussinesq M. Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17(1):108\u201316.","journal-title":"Lancet Infect Dis"},{"key":"2655_CR4","volume-title":"Accelerating work to overcome the global impact of neglected tropical diseases - a roadmap for implementation","author":"WHO","year":"2012","unstructured":"WHO. Accelerating work to overcome the global impact of neglected tropical diseases - a roadmap for implementation. Geneva: World Health Organization; 2012. WHO\/HTM\/NTD\/PCT\/2012.1. Available: \n                    http:\/\/www.who.int\/neglected_diseases\/NTD_RoadMap_2012_Fullversion.pdf\n                    \n                  . Accessed 13 Jan 2018"},{"issue":"7","key":"2655_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.pt.2012.04.005","volume":"28","author":"A Crump","year":"2012","unstructured":"Crump A, Morel CM, Omura S. The onchocerciasis chronicle: from the beginning to the end? Trends Parasitol. 2012;28(7):280\u20138.","journal-title":"Trends Parasitol"},{"issue":"10","key":"2655_CR6","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","volume":"2","author":"EA Ottesen","year":"2008","unstructured":"Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis. 2008;2(10):e317.","journal-title":"PLoS Negl Trop Dis"},{"key":"2655_CR7","doi-asserted-by":"crossref","unstructured":"Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, et al. Global Programme to Eliminate Lymphatic Filariasis: the processes underlying programme success. PLoS Negl Trop Dis. 2014;8(12):e3328.","DOI":"10.1371\/journal.pntd.0003328"},{"issue":"38","key":"2655_CR8","first-page":"22","volume":"14","author":"JL Sturchio","year":"2001","unstructured":"Sturchio JL. The case of ivermectin: lessons and implications for improving access to care and treatment in developing countries. Community Eye Health. 2001;14(38):22\u20133.","journal-title":"Community Eye Health"},{"issue":"7","key":"2655_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1586\/14787210.2013.811841","volume":"11","author":"MP Rebollo","year":"2013","unstructured":"Rebollo MP, Bockarie MJ. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame. Expert Rev Anti-Infect Ther. 2013;11(7):723\u201331.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"5","key":"2655_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1473-3099(08)70099-9","volume":"8","author":"MG Bas\u00e1\u00f1ez","year":"2008","unstructured":"Bas\u00e1\u00f1ez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(5):310\u201322.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2655_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1365-3156.2006.01606.x","volume":"11","author":"ME de Kraker","year":"2006","unstructured":"de Kraker ME, Stolk WA, van Oortmarssen GJ, Habbema JD. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Tropical Med Int Health. 2006;11(5):718\u201328.","journal-title":"Tropical Med Int Health"},{"key":"2655_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.epidem.2017.02.002","volume":"18","author":"L Dyson","year":"2017","unstructured":"Dyson L, Stolk WA, Farrell SH, Hollingsworth TD. Measuring and modelling the effects of systematic non-adherence to mass drug administration. Epidemics. 2017;18:56\u201366.","journal-title":"Epidemics"},{"key":"2655_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/bs.apar.2014.12.005","volume":"87","author":"WA Stolk","year":"2015","unstructured":"Stolk WA, Stone C, de Vlas SJ. Modelling lymphatic filariasis transmission and control: modelling frameworks, lessons learned and future directions. Adv Parasitol. 2015;87:249\u201391.","journal-title":"Adv Parasitol"},{"issue":"4","key":"2655_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0001-706X(91)90015-C","volume":"48","author":"AP Plaisier","year":"1991","unstructured":"Plaisier AP, van Oortmarssen GJ, Remme J, Habbema JD. The reproductive lifespan of Onchocerca volvulus in west African savanna. Acta Trop. 1991;48(4):271\u201384.","journal-title":"Acta Trop"},{"issue":"3","key":"2655_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpddr.2016.04.002","volume":"6","author":"AC Kuesel","year":"2016","unstructured":"Kuesel AC. Research for new drugs for elimination of onchocerciasis in Africa. Int J Parasitol Drugs Drug Resist. 2016;6(3):272\u201386.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"3","key":"2655_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/civ882","volume":"62","author":"EK Thomsen","year":"2016","unstructured":"Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis. Clin Infect Dis. 2016;62(3):334\u201341.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2655_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","volume":"17","author":"MA Irvine","year":"2017","unstructured":"Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis. 2017;17(4):451\u20138.","journal-title":"Lancet Infect Dis"},{"key":"2655_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/1756-3305-7-363","volume":"7","author":"DH Molyneux","year":"2014","unstructured":"Molyneux DH, Hopkins A, Bradley MH, Kelly-Hope LA. Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: a can of worms. Parasit Vectors. 2014;7:363.","journal-title":"Parasit Vectors"},{"issue":"8448","key":"2655_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0140-6736(85)91496-5","volume":"2","author":"M Lariviere","year":"1985","unstructured":"Lariviere M, Vingtain P, Aziz M, Beauvais B, Weimann D, Derouin F, et al. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet. 1985;2(8448):174\u201347.","journal-title":"Lancet"},{"issue":"9070","key":"2655_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","volume":"350","author":"J Gardon","year":"1997","unstructured":"Gardon J, Gardon-Wendel N. Demanga Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18\u201322.","journal-title":"Lancet"},{"issue":"8","key":"2655_CR21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/cid\/cix016","volume":"64","author":"JA Herrick","year":"2017","unstructured":"Herrick JA, Legrand F, Gounoue R, Nchinda G, Montavon C, Bopda J, et al. Posttreatment reactions after single-dose diethylcarbamazine or ivermectin in subjects with Loa loa infection. Clin Infect Dis. 2017;64(8):1017\u201325.","journal-title":"Clin Infect Dis"},{"issue":"9235","key":"2655_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0140-6736(00)02733-1","volume":"356","author":"MC Thomson","year":"2000","unstructured":"Thomson MC, Obsomer V, Dunne M, Connor SJ, Molyneux DH. Satellite mapping of Loa loa prevalence in relation to ivermectin use in west and central Africa. Lancet. 2000;356(9235):1077\u20138.","journal-title":"Lancet"},{"key":"2655_CR23","volume-title":"Provisional strategy for interrupting LF transmission in loiasis-endemic countries","author":"WHO","year":"2012","unstructured":"WHO. Provisional strategy for interrupting LF transmission in loiasis-endemic countries. Geneva: World Health Organization; 2012. WHO\/HTM\/NTD\/PCT\/2012.6. Available: \n                    http:\/\/www.who.int\/lymphatic_filariasis\/resources\/who_htm_ntd_pct_2012.6\/en\/\n                    \n                  . Accessed 13 Jan 2018"},{"issue":"2","key":"2655_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1179\/000349803235001697","volume":"97","author":"K Awadzi","year":"2003","unstructured":"Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, et al. The co-administration of ivermectin and albendazole - safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2003;97(2):165\u201378.","journal-title":"Ann Trop Med Parasitol"},{"key":"2655_CR25","volume-title":"Guidelines for use of Mectizan in areas co-endemic for onchocerciasis and loiasis","author":"Mectizan Expert Committee\/APOC Technical Consultative Committee","year":"2004","unstructured":"Mectizan Expert Committee\/APOC Technical Consultative Committee. Guidelines for use of Mectizan in areas co-endemic for onchocerciasis and loiasis. Geneva: MEC\/APOC; 2004. Available: \n                    http:\/\/www.who.int\/apoc\/publications\/englishmectccloarecs-june04.pdf\n                    \n                  . Accessed 13 Jan 2018"},{"issue":"Suppl. 1","key":"2655_CR26","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/1475-2883-2-S1-S9","volume":"2","author":"DG Addiss","year":"2003","unstructured":"Addiss DG, Rheingans R, Twum-Danso NA, Richards FO. A framework for decision-making for mass distribution of Mectizan(R) in areas endemic for Loa loa. Filaria J. 2003;2(Suppl. 1):S9.","journal-title":"Filaria J"},{"issue":"286","key":"2655_CR27","doi-asserted-by":"publisher","first-page":"286re4","DOI":"10.1126\/scitranslmed.aaa3480","volume":"7","author":"MV D\u2019Ambrosio","year":"2015","unstructured":"D\u2019Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, et al. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med. 2015;7(286):286re4.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2655_CR28","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1128\/JCM.00525-14","volume":"52","author":"PM Drame","year":"2014","unstructured":"Drame PM, Fink DL, Kamgno J, Herrick JA, Nutman TB. Loop-mediated isothermal amplification for rapid and semiquantitative detection of Loa loa infection. J Clin Microbiol. 2014;52(6):2071\u20137.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2655_CR29","doi-asserted-by":"publisher","first-page":"e00456","DOI":"10.1128\/mBio.00456-16","volume":"7","author":"TG Geary","year":"2016","unstructured":"Geary TG. A step toward eradication of human filariases in areas where Loa is endemic. MBio. 2016;7(2):e00456\u201316.","journal-title":"MBio"},{"issue":"1","key":"2655_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S0031182013001108","volume":"141","author":"MJ Taylor","year":"2014","unstructured":"Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology. 2014;141(1):119\u201327.","journal-title":"Parasitology"},{"issue":"5","key":"2655_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00436-003-0872-z","volume":"90","author":"MP Grobusch","year":"2003","unstructured":"Grobusch MP, Kombila M, Autenrieth I, Mehlhorn H, Kremsner PG. No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans. Parasitol Res. 2003;90(5):405\u20138.","journal-title":"Parasitol Res"},{"issue":"8","key":"2655_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/cid\/ciu1152","volume":"60","author":"M Walker","year":"2015","unstructured":"Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Bas\u00e1\u00f1ez MG. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin Infect Dis. 2015;60(8):1199\u2013207.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2655_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.parepi.2017.05.001","volume":"2","author":"M Brito","year":"2017","unstructured":"Brito M, Paulo R, Van-Dunem P, Martins A, Unnasch TR, Novak RJ, et al. Rapid integrated clinical survey to determine prevalence and co-distribution patterns of lymphatic filariasis and onchocerciasis in a Loa loa co-endemic area: the Angolan experience. Parasite Epidemiol Control. 2017;2(3):71\u201384.","journal-title":"Parasite Epidemiol Control"},{"key":"2655_CR34","doi-asserted-by":"crossref","unstructured":"Zour\u00e9 HG, Noma M, Tekle AH, Amazigo UV, Diggle PJ, Giorgi E, et al. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasit Vectors. 2014;7:326.","DOI":"10.1186\/1756-3305-7-326"},{"issue":"1","key":"2655_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s13071-015-1166-x","volume":"8","author":"P Moraga","year":"2015","unstructured":"Moraga P, Cano J, Baggaley R, Gyapong J, Njenga S, Nikolay B, et al. Modelling the distribution and transmission intensity of lymphatic filariasis in sub-Saharan Africa prior to scaling up interventions: integrated use of geostatistical and mathematical modelling. Parasit Vectors. 2015;8(1):560.","journal-title":"Parasit Vectors"},{"key":"2655_CR36","doi-asserted-by":"crossref","unstructured":"Zour\u00e9 HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis. 2011;5(6):e1210.","DOI":"10.1371\/journal.pntd.0001210"},{"key":"2655_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1756-3305-7-307","volume":"7","author":"LA Kelly-Hope","year":"2014","unstructured":"Kelly-Hope LA, Cano J, Stanton MC, Bockarie MJ, Molyneux DH. Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping. Parasit Vectors. 2014;7:307.","journal-title":"Parasit Vectors"},{"issue":"9","key":"2655_CR38","doi-asserted-by":"publisher","first-page":"e2416","DOI":"10.1371\/journal.pntd.0002416","volume":"7","author":"PN Okorie","year":"2013","unstructured":"Okorie PN, Ademowo GO, Saka Y, Davies E, Okoronkwo C, Bockarie MJ, et al. Lymphatic filariasis in Nigeria; micro-stratification overlap mapping (MOM) as a prerequisite for cost-effective resource utilization in control and surveillance. PLoS Negl Trop Dis. 2013;7(9):e2416.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2655_CR39","doi-asserted-by":"publisher","first-page":"e0004328","DOI":"10.1371\/journal.pntd.0004328","volume":"10","author":"SJ O'Hanlon","year":"2016","unstructured":"O'Hanlon SJ, Slater HC, Cheke RA, Boatin BA, Coffeng LE, Pion SD, et al. Model-based geostatistical mapping of the prevalence of Onchocerca volvulus in West Africa. PLoS Negl Trop Dis. 2016;10(1):e0004328.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"2655_CR40","doi-asserted-by":"publisher","first-page":"e0003400","DOI":"10.1371\/journal.pntd.0003400","volume":"9","author":"RM Flueckiger","year":"2015","unstructured":"Flueckiger RM, Nikolay B, Gelderblom HC, Smith JL, Haddad D, Tack W, et al. Integrating data and resources on neglected tropical diseases for better planning: the NTD mapping tool (NTDmap.org). PLoS Negl Trop Dis. 2015;9(2):e0003400.","journal-title":"PLoS Negl Trop Dis"},{"key":"2655_CR41","unstructured":"Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN): NTD portal. Available: \n                    http:\/\/ntd.afro.who.int\/en\/espen\/home\n                    \n                  . Accessed 13 Jan 2018."},{"key":"2655_CR42","unstructured":"World Health Organization. Neglected tropical diseases. PCT Databank - Country Profiles 2010. Available: \n                    http:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/databank\/CP_CountryName.pdf\n                    \n                  . Accessed 13 Jan 2018."},{"key":"2655_CR43","volume-title":"Operational guidelines for rapid mapping of bancroftian filariasis in Africa (WHO\/CDS\/CPE\/CEE\/2000.9)","author":"WHO","year":"2000","unstructured":"WHO. Operational guidelines for rapid mapping of bancroftian filariasis in Africa (WHO\/CDS\/CPE\/CEE\/2000.9). Geneva: World Health Organization; 2000. Available: \n                    http:\/\/www.who.int\/lymphatic_filariasis\/resources\/who_cds_cpe_cee_2000.9\/en\/\n                    \n                  . Accessed 13 Jan 2018"},{"key":"2655_CR44","unstructured":"African Programme for Onchocerciasis Control. Guidelines for revising ivermectin treatment boundaries within the context of onchocerciasis elimination. WHO\/MG\/15.21. Geneva: World Health Organization; 2015. Available: \n                    http:\/\/www.who.int\/apoc\/ATS_Report_Annex1_APOC_Guidelines_for_revising_IVM_Tx_boundaries.pdf\n                    \n                  . Accessed 13 Jan 2018."},{"key":"2655_CR45","series-title":"WHO\/APOC\/MG\/10.1","volume-title":"Conceptual and operational framework of Onchocerciasis elimination with Ivermectin treatment","author":"African Programme for Onchocerciasis Control","year":"2010","unstructured":"African Programme for Onchocerciasis Control. Conceptual and operational framework of Onchocerciasis elimination with Ivermectin treatment, WHO\/APOC\/MG\/10.1. Geneva: World Health Organization; 2010. Available: \n                    http:\/\/www.who.int\/apoc\/oncho_elimination_report_english.pdf\n                    \n                  . Accessed 13 Jan 2018"},{"issue":"9","key":"2655_CR46","doi-asserted-by":"publisher","first-page":"e1825","DOI":"10.1371\/journal.pntd.0001825","volume":"6","author":"MO Traore","year":"2012","unstructured":"Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6(9):e1825.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"2655_CR47","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1371\/journal.pntd.0000497","volume":"3","author":"L Diawara","year":"2009","unstructured":"Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3(7):e497.","journal-title":"PLoS Negl Trop Dis"},{"key":"2655_CR48","doi-asserted-by":"crossref","unstructured":"Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna state, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors. 2012;5:28.","DOI":"10.1186\/1756-3305-5-28"},{"issue":"5","key":"2655_CR49","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4269\/ajtmh.16-0274","volume":"95","author":"IM Zarroug","year":"2016","unstructured":"Zarroug IM, Hashim K, ElMubark WA, Shumo ZA, Salih KA, ElNojomi NA, et al. The first confirmed elimination of an onchocerciasis focus in Africa: Abu Hamed, Sudan. Am J Trop Med Hyg. 2016;95(5):1037\u201340.","journal-title":"Am J Trop Med Hyg"},{"key":"2655_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.actatropica.2016.12.029","volume":"167","author":"T Lakwo","year":"2017","unstructured":"Lakwo T, Garms R, Wamani J, Tukahebwa EM, Byamukama E, Onapa AW, et al. Interruption of the transmission of Onchocerca volvulus in the Kashoya-Kitomi focus, western Uganda by long-term ivermectin treatment and elimination of the vector Simulium neavei by larviciding. Acta Trop. 2017;167:128\u201336.","journal-title":"Acta Trop"},{"issue":"3","key":"2655_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.actatropica.2013.02.016","volume":"126","author":"TL Lakwo","year":"2013","unstructured":"Lakwo TL, Garms R, Rubaale T, Katabarwa M, Walsh F, Habomugisha P, et al. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector Simulium neavei and 19 years of annual ivermectin treatments. Acta Trop. 2013;126(3):218\u201321.","journal-title":"Acta Trop"},{"key":"2655_CR52","doi-asserted-by":"crossref","unstructured":"Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiaga\u00ef J, et al. Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon. Am J Trop Med Hyg. 2011;85(6):1041\u20139.","DOI":"10.4269\/ajtmh.2011.11-0333"},{"issue":"2","key":"2655_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4269\/ajtmh.13-0037","volume":"89","author":"MN Katabarwa","year":"2013","unstructured":"Katabarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, et al. Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin. Am J Trop Med Hyg. 2013;89(2):293\u2013300.","journal-title":"Am J Trop Med Hyg."},{"issue":"2","key":"2655_CR54","doi-asserted-by":"publisher","first-page":"e0004392","DOI":"10.1371\/journal.pntd.0004392","volume":"10","author":"A Eisenbarth","year":"2016","unstructured":"Eisenbarth A, Achukwi MD, Renz A. Ongoing transmission of Onchocerca volvulus after 25 years of annual ivermectin mass treatments in the Vina du Nord river valley, in North Cameroon. PLoS Negl Trop Dis. 2016;10(2):e0004392.","journal-title":"PLoS Negl Trop Dis"},{"key":"2655_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.epidem.2017.02.005","volume":"18","author":"M Walker","year":"2017","unstructured":"Walker M, Stolk WA, Dixon MA, Bottomley C, Diawara L, Traore MO, et al. Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal. Epidemics. 2017;18:4\u201315.","journal-title":"Epidemics"},{"issue":"12","key":"2655_CR56","doi-asserted-by":"publisher","first-page":"e0005198","DOI":"10.1371\/journal.pntd.0005198","volume":"10","author":"NO Wilson","year":"2016","unstructured":"Wilson NO, Badara Ly A, Cama VA, Cantey PT, Cohn D, Diawara L, et al. Evaluation of lymphatic filariasis and onchocerciasis in three Senegalese districts treated for onchocerciasis with ivermectin. PLoS Negl Trop Dis. 2016;10(12):e0005198.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"2655_CR57","doi-asserted-by":"publisher","first-page":"e31743","DOI":"10.1371\/journal.pone.0031743","volume":"7","author":"C Linard","year":"2012","unstructured":"Linard C, Gilbert M, Snow RW, Noor AM, Tatem AJ. Population distribution, settlement patterns and accessibility across Africa in 2010. PLoS One. 2012;7(2):e31743.","journal-title":"PLoS One"},{"issue":"3","key":"2655_CR58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1473-3099(14)71050-3","volume":"15","author":"B Speich","year":"2015","unstructured":"Speich B, Ali SM, Ame SM, Bogoch II, Alles R, Huwyler J, et al. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis. 2015;15(3):277\u201384.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2655_CR59","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2174\/138920112800399248","volume":"13","author":"P Gonzalez","year":"2012","unstructured":"Gonzalez P, Gonzalez FA, Ueno K. Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr Pharm Biotechnol. 2012;13(6):1103\u20139.","journal-title":"Curr Pharm Biotechnol"},{"key":"2655_CR60","unstructured":"World Health Organization. Neglected tropical diseases. Preventive Chemotherapy databank. Available: \n                    http:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/databank\/en\/index.htm\n                    \n                  . Accessed 13 Jan 2018."},{"key":"2655_CR61","doi-asserted-by":"crossref","unstructured":"Wanji S, Amvongo-Adjia N, Koudou B, Njouendou AJ, Chounna Ndongmo PW, Kengne-Ouafo JA, et al. Cross-reactivity of filariais ICT cards in areas of contrasting endemicity of Loa loa and Mansonella perstans in Cameroon: implications for shrinking of the lymphatic filariasis map in the Central African region. PLoS Negl Trop Dis. 2015;9(11):e0004184.","DOI":"10.1371\/journal.pntd.0004184"},{"issue":"6","key":"2655_CR62","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.4269\/ajtmh.16-0547","volume":"95","author":"SDS Pion","year":"2016","unstructured":"Pion SDS, Montavon C, Chesnais CB, Kamgno J, Wanji S, Klion AD, et al. Positivity of antigen tests used for diagnosis of lymphatic filariasis in individuals without Wuchereria bancrofti infection but with high Loa loa microfilaremia. Am J Trop Med Hyg. 2016;95(6):1417\u201323.","journal-title":"Am J Trop Med Hyg"},{"key":"2655_CR63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13071-016-1556-8","volume":"9","author":"S Wanji","year":"2016","unstructured":"Wanji S, Amvongo-Adjia N, Njouendou AJ, Kengne-Ouafo JA, Ndongmo WP, Fombad FF, et al. Further evidence of the cross-reactivity of the Binax NOW(R) Filariasis ICT cards to non-Wuchereria bancrofti filariae: experimental studies with Loa loa and Onchocerca ochengi. Parasit Vectors. 2016;9:267.","journal-title":"Parasit Vectors"},{"key":"2655_CR64","doi-asserted-by":"crossref","unstructured":"Kouam MK, Tchatchueng-Mbougua JB, Demanou M, Boussinesq M, Pion SDS, Kamgno J. Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon. Parasit Vectors 2013;6(1):283.","DOI":"10.1186\/1756-3305-6-283"},{"issue":"4","key":"2655_CR65","doi-asserted-by":"publisher","first-page":"e0003664","DOI":"10.1371\/journal.pntd.0003664","volume":"9","author":"YE Kim","year":"2015","unstructured":"Kim YE, Remme JHF, Steinmann P, Stolk WA, Roungou J-B, Tediosi F. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl Trop Dis. 2015;9(4):e0003664.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"2655_CR66","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.trstmh.2007.10.009","volume":"102","author":"HP Duerr","year":"2008","unstructured":"Duerr HP, Raddatz G, Eichner M. Diagnostic value of nodule palpation in onchocerciasis. Trans R Soc Trop Med Hyg. 2008;102(2):148\u201354.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"2655_CR67","first-page":"311","volume":"44","author":"P Fischer","year":"1993","unstructured":"Fischer P, Kipp W, Bamuhiga J, Binta-Kahwa J, Kiefer A, B\u00fcttner DW. Parasitological and clinical characterization of Simulium neavei-transmitted onchocerciasis in western Uganda. Trop Med Parasitol. 1993;44(4):311\u201321.","journal-title":"Trop Med Parasitol"},{"key":"2655_CR68","unstructured":"African Programme for Onchocerciasis Control. The WHO African Programme for Onchocerciasis Control Progress Report 2013 (1st September 2012 - 31st August 2013). JAF19.5. World Health Organization\/APOC; 2013. Available: \n                    http:\/\/www.who.int\/apoc\/publications\/JAF195_EN_APOC_PR2013_OK.pdf?ua=1\n                    \n                  . Accessed 13 Jan 2018."},{"issue":"9","key":"2655_CR69","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1046\/j.1365-3156.2003.01091.x","volume":"8","author":"NA Twum-Danso","year":"2003","unstructured":"Twum-Danso NA, Meredith SE. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis. Tropical Med Int Health. 2003;8(9):820\u201331.","journal-title":"Tropical Med Int Health"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-018-2655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-018-2655-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-018-2655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:01:24Z","timestamp":1589547684000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-018-2655-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2655"],"URL":"https:\/\/doi.org\/10.1186\/s13071-018-2655-5","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"70"}}